title: Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16.
abstract: Adult T cell leukemia/lymphoma (ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). Two patients achieved complete remission, lasting 12 months and more than 8 months, and 2 others partial remission, lasting 2 months and 6 weeks, respectively. The major toxicity was myelosuppression. Other toxicities were not severe and were well tolerable. Orally administered MST-16 is a promising agent for the treatment of ATLL.
authors.affiliation: Department of Medicine, Branch Hospital, Nagoya University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ichihashi
authors.forename: H
authors.initials: H
authors.lastname: Kiyoi
authors.forename: H
authors.initials: H
authors.lastname: Fukutani
authors.forename: K
authors.initials: K
authors.lastname: Kubo
authors.forename: T
authors.initials: T
authors.lastname: Yamauchi
authors.forename: T
authors.initials: T
authors.lastname: Naoe
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: R
authors.initials: R
authors.lastname: Ohno
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D010879:Piperazines; C057773:sobuzoxane